ePrivacy and GPDR Cookie Consent by TermsFeed Generator

Detail of the clinical trial

Title of the trial Open-label, randomized, multicenter, phase III trial of dasatinib (SPRYCEL) vs. standard dose imatinib (400 mg) in the treatment of subjects with newly diagnosed chronic phase phildelphia chromosome positive chronic myeloid leukemia
EudraCT number 2006-005712-27
Protocol number CA180-056
Sponsor Bristol-Myers Squibb International, Belgie
Indications Hemato-oncology
Diagnosis Chronic Myeloid Leukemia
Population in clinical trial Adults (18-65 years)
Elderly ( > 65 years)
Year of receiving the request to Institute (SÚKL) 2007
Date of approval by Institute (SÚKL) 17.09.2007
Date of approval by EC 12.9.2007
Date of initiation CT in ČR 06.12.2007
Date of ending CT in ČR 16.9.2014
Sites Interní hematoonkologická klinika, FN Brno
Ústav hematologie a krevní transfúze, VFN v Praze
2. interní klinika - Oddělení klinické hematologie, FN Hradec Králové
FN Olomouc

‹‹ Back to list